Neuropace/$NPCE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neuropace
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
- Ticker
- $NPCE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 220
- Headquarters
- Mountain View, United States
- Website
- www.neuropace.com
Neuropace Metrics
BasicAdvanced
$423M
-
-$0.57
1.93
-
Price and volume
Market cap
$423M
Beta
1.93
52-week high
$19.60
52-week low
$9.23
Average daily volume
120K
Financial strength
Current ratio
4.944
Quick ratio
3.822
Long term debt to equity
5.695
Total debt to equity
5.885
Interest coverage (TTM)
-1.92%
Profitability
EBITDA (TTM)
-11.877
Gross margin (TTM)
77.38%
Net profit margin (TTM)
-17.86%
Operating margin (TTM)
-11.34%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-7.47%
Return on equity (TTM)
-103.27%
Valuation
Price to revenue (TTM)
3.865
Price to book
35.51
Price to tangible book (TTM)
35.51
Price to free cash flow (TTM)
-35.616
Free cash flow yield (TTM)
-2.81%
Free cash flow per share (TTM)
-0.346
Growth
Revenue change (TTM)
33.16%
Earnings per share change (TTM)
-32.16%
3-year revenue growth (CAGR)
24.89%
3-year earnings per share growth (CAGR)
-30.50%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Analyst projections of the future price of Neuropace stock.
Bulls say / Bears say
Core RNS demand is still expanding: second-quarter RNS revenue rose 21.3% year on year, and NeuroPace raised 2026 revenue guidance to $99.5 million–$101.5 million, implying 21%–23% growth in existing indications. (NeuroPace, Inc.)
In the NAUTILUS trial, 18-month results showed a 77% median reduction in generalised tonic-clonic seizures, alongside fewer injury events and less rescue-medication use. FDA clearance for idiopathic generalised epilepsy could open a new patient group, although that expansion is not yet approved. (NeuroPace, Inc.)
Second-quarter gross margin was 82.8%, while the net loss narrowed to $6.2 million from $10.0 million a year earlier and the adjusted EBITDA loss improved by $2.1 million. Continued growth against a high-margin base could strengthen operating leverage. (NeuroPace, Inc.)
The FDA said the IGE application was not approvable in its current form and requested additional information on the clinical evidence. The regulatory path and timing remain uncertain, and 2026 revenue guidance excludes any contribution from IGE. (U.S. Securities and Exchange Commission, NeuroPace, Inc.)
The company remains loss-making: it used $9.8 million of operating cash in the first half of 2026 and had $51.7 million in cash and short-term investments against $59.0 million of long-term debt. Ongoing losses could leave it needing additional funding before it reaches sustainable cash generation. (U.S. Securities and Exchange Commission)
Even if the IGE indication is approved, payer coverage may slow adoption: management said private insurers would need to update their policies and expected that process to take about a year. That could make the potential market opportunity slower to convert into sales. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neuropace News
AllArticlesVideos
Funds containing Neuropace
Fund name | Fund size | $NPCE weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.